Dementia

Kingman, AZ

65 Dementia Trials near Kingman, AZ

Power is an online platform that helps thousands of Dementia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Zoledronic Acid for Parkinson's Disease

Scottsdale, Arizona
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:60+

2650 Participants Needed

ML-007C-MA for Alzheimer's Disease Psychosis

Scottsdale, Arizona
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 90

300 Participants Needed

Donanemab for Early Alzheimer's Disease

Chandler, Arizona
This trial is testing different doses of donanemab, a drug aimed at helping people with early Alzheimer's disease. Donanemab has shown rapid reduction of brain amyloid in early Alzheimer's disease. The study will look at how often and how severely participants experience a side effect involving brain swelling. Researchers also want to find out which patient characteristics might predict this side effect.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85

1175 Participants Needed

NMRA-323511 for Agitation in Alzheimer's Disease

Chandler, Arizona
This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly. Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease. Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment. Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:55 - 90

96 Participants Needed

KarXT + KarX-EC for Alzheimer's Disease

Redlands, California
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:60 - 85

586 Participants Needed

Trontinemab for Alzheimer's Disease

Riverside, California
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 90

800 Participants Needed

AVP-786 for Agitation in Alzheimer's Disease

Oceanside, California
This trial tests a combination of two drugs taken by mouth to help calm severe agitation in people with Alzheimer's disease by balancing brain chemicals.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50 - 90

183 Participants Needed

Care Program for Dementia Caregivers

Carlsbad, California
The purpose of the study is to develop and test the feasibility of a nonmedical digital health intervention, the Spanish-language Caregiver-Enabled Care Program (CECP), with Spanish-speaking caregivers of persons with dementia (PWD). CECP is a nonmedical digital population health intervention that provides personalized education, proactive 1:1 human coaching, and remote monitoring, all delivered via a dedicated tablet shipped to the caregiver's home at no cost to the caregiver or PWD. For this study, the investigators are recruiting 135 patient/caregiver dyads.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

270 Participants Needed

Xanamem for Alzheimer's Disease

Carlsbad, California
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50+

220 Participants Needed

Androgen Receptor Therapies for Prostate Cancer

Los Angeles, California
This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. The investigators use MRI imaging (non-invasive, non-contrast) to see whether there are changes in brain structure or activity related to treatment that may be related to changes in cognitive function. The investigators are also looking for genetic variations that might make patients more or less sensitive to cognitive changes during treatment for prostate cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Sex:Male

100 Participants Needed

Piromelatine for Alzheimer's Disease

Santa Ana, California
This trial tests piromelatine, a pill taken before bed, in people with mild Alzheimer's who lack a specific genetic variation. The goal is to see if it can improve brain function and slow down dementia progression.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:60 - 85

225 Participants Needed

LY3372689 for Alzheimer's Disease

Carlsbad, California
This trial is testing a new drug, LY3372689, on people with early symptoms of Alzheimer's Disease to see if it is safe and how it affects their symptoms.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:60 - 85

330 Participants Needed

Sleep Health Program for Alzheimer's Disease

La Jolla, California
This trial tests the Care2Sleep program, which helps people improve their sleep through several educational sessions. It targets pairs of people and caregivers to enhance their sleep, health, and quality of life. The program is available both in-person and online.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

672 Participants Needed

CHW Home Visit + Wearable Tech for Dementia Caregivers

Irvine, California
The proposed study will test a 3-month, community health worker (CHW) delivered home visit, culturally and language-appropriate intervention for ethnic and underserved dementia family caregivers of persons with dementia (PWD) using wearable technology for real time monitoring of caregivers' stress and sleep. The CHW delivered home visit intervention includes stress reduction techniques by mindful deep breathing and compassionate support/listening and caregiving education to improve caregiver's health, wellbeing, and positive interactions with the PWD. This dementia caregiver study using wearable technology has the potential to significantly lessen health disparities in dementia care, assisting underserved ethnic dementia caregivers in self-management and increasing their quality of life.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

332 Participants Needed

Masupirdine for Agitation in Alzheimer's Disease

Anaheim, California
This trial will test a medication called masupirdine, which participants will take regularly. It targets people with Alzheimer's disease who are experiencing agitation. The study aims to see if masupirdine can help reduce agitation and ensure it is safe and well-tolerated. Masupirdine has been previously evaluated in patients with moderate Alzheimer's disease and was found to be generally safe and well-tolerated.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 90

375 Participants Needed

ITI-1284 for Agitation in Dementia

Anaheim, California
This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:55+

320 Participants Needed

Brain Longevity Supplement for Cognitive Functioning

Encinitas, California
This is a parallel group, randomized, double-blind, placebo-controlled clinical study assessing the safety and effects of a novel nutritional product on self-reported cognitive function and health in adults that reside in the USA. Participants will take their assigned study product (active or placebo) for 8 weeks and answer validated electronic surveys assessing cognitive function delivered to them through a text message (SMS) link or through email.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:40+

650 Participants Needed

IV Acetaminophen for Delirium After Cardiac Surgery

Irvine, California
Our objective is to find an effective prophylactic intervention by evaluating IV acetaminophen's impact in reducing the frequency of postoperative delirium, one of the most common and detrimental complications of cardiac surgery in older adults.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60+

900 Participants Needed

MRI + PET Scans for Cognitive Impairment

Irvine, California
The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this study includes additional PET scans to examine the relationship between tau protein in the brain and cognitive decline. Tau is a protein that is known to form tangles in the areas of the brain important for memory, and these tau tangles are a hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation in the brain using an investigational drug called MK-6240, which is a radio tracer that gets injected prior to a positron emission tomography (PET) scan.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:60+

300 Participants Needed

ACP-204 for Hallucinations

Irvine, California
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 84

180 Participants Needed

Why Other Patients Applied

"I watched my mother die from Parkinson’s. At the time of her death, she weighed 85 pounds and could not move any muscles voluntarily except her eyelids. I would like to participate in a trial to help find a better treatment for PD than what is currently available. It is a devastating illness. It breaks my heart that other families will have to go through this."

WU
Healthy Volunteer PatientAge: 76

"I have been on standard Alzheimer's medication for a few years but know this treatment only works to delay my cognitive deterioration, not improve it. I've been doing research, which brought me here, to consider some of the latest research drugs. While I know that there's no guarantee that a clinical trial improves my condition, I'd like to give one a try and help further the research for all."

VL
Alzheimer's PatientAge: 71

"I watched my mother suffer through years of Alzheimer's Disease and I want to help advance the science for treating AD. I don't want anyone else to have go through what our family went through."

OF
Alzheimer's Disease PatientAge: 65

"I have a very strong family history of Alzheimer’s, with my maternal grandmother, mother, uncle, and sister having the disease. My APOE status is 2/4. My memory is going, although 6 months ago I tested decently on some cognitive tests. I'd like to help myself by getting ahead of my condition and help others in a similar situation by participating in medical research."

EK
Mild Cognitive Impairment PatientAge: 72

"I'm so used to losing things, forgetting things, making up to acronyms to remember things only to remember the acromym but not what the letters stand for... I enter a new room to look for an item, only to forget what I was looking for. I've discussed the existing treatments with my neurologist and she's on board with my joining a clinical trial."

AH
Dementia PatientAge: 64

KarXT + KarX-EC for Alzheimer's Disease

Irvine, California
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:60 - 85

586 Participants Needed

ADEL-Y01 for Alzheimer's Disease

Anaheim, California
This is a Phase Ia/Ib, two-part, randomized, placebo-controlled, double-blinded, first in human(FIH) study to evaluate the safety, tolerability, PK, and PD of ADEL-Y01 in healthy participants in Part 1 and participants with MCI due to AD and mild AD in Part 2. The study includes 2 parts: Part 1 (single ascending dose \[SAD\] and Part 2 (multiple ascending dose \[MAD\]).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

73 Participants Needed

Trontinemab for Alzheimer's Disease

Santa Ana, California
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 90

800 Participants Needed

Remternetug for Alzheimer's Disease

La Jolla, California
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

280 Participants Needed

Gantenerumab for Alzheimer's Disease

La Jolla, California
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

280 Participants Needed

Investigational Alzheimer's Drugs for Early Onset Alzheimer's Disease

La Jolla, California
This trial tests two drugs, lecanemab and E2814, in people with a genetic mutation that causes Alzheimer's disease. Lecanemab helps remove harmful protein clumps from the brain, while E2814 prevents harmful protein tangles from forming. The goal is to see if these drugs can slow down or improve symptoms of Alzheimer's.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3

197 Participants Needed

Disease-Modifying Drugs for Alzheimer's Disease

La Jolla, California
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3

490 Participants Needed

Lecanemab for Alzheimer's Disease

La Jolla, California
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

43 Participants Needed

Financial Incentive for Dementia Research Participation

Chula Vista, California
Women, older adults, individuals from communities of color, particularly Black and Latino persons, and individuals with lower socioeconomic status are historically underrepresented in clinical research. This is true across a range of clinical areas but no more so than in Alzheimer's Disease Research. The purpose of this study is to assess whether offering small $25 financial incentives can increase enrollment of diverse community members to the Alzheimer's Prevention Trial (APT) Webstudy, a memory concerns registry meant to accelerate clinical trials, relative to non-monetary incentives such as a reusable grocery bag. To do this we will test in-person recruitment efforts at community events and locations, such as Northgate Gonzalez Market locations and local food bank events. We also aim to compare the relative cost of recruiting an additional person to the APT Webstudy.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50+

400 Participants Needed

TabCAT Assessment for Dementia

Pasadena, California
Efficient and user-friendly paradigms to detect cognitive impairment, including dementia are needed in primary care. The TabCAT Brain Health Assessment accurately detects cognitive impairment via an appealing tablet interface with automated scoring and EMR integration. This study will evaluate the effectiveness of the paradigm on detection rates and other brain health outcomes via a pragmatic cluster randomized trial in 26 Kaiser Southern California primary care clinics.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

180000 Participants Needed

123

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Dementia clinical trials in Kingman, AZ pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Dementia clinical trials in Kingman, AZ work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Dementia trials in Kingman, AZ 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Kingman, AZ for Dementia is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Kingman, AZ several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Dementia medical study in Kingman, AZ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Dementia clinical trials in Kingman, AZ?

Most recently, we added Trontinemab for Alzheimer's Disease, Trontinemab for Alzheimer's Disease and ML-007C-MA for Alzheimer's Disease Psychosis to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Arizona

Anxiety Clinical Trials in Arizona

Schizophrenia Clinical Trials in Arizona

ADHD Clinical Trials in Arizona

Bipolar Disorder Clinical Trials in Arizona

Multiple Sclerosis Clinical Trials in Arizona

Autism Clinical Trials in Arizona

Treatment Resistant Depression Clinical Trials in Arizona

Borderline Personality Disorder Clinical Trials in Arizona

Social Anxiety Disorder Clinical Trials in Arizona

Parkinson's Disease Clinical Trials in Arizona

Alzheimer's Disease Clinical Trials in Arizona

By Location

Clinical Trials near Phoenix, AZ

Clinical Trials near Tucson, AZ

Clinical Trials near Scottsdale, AZ

Clinical Trials near Mesa, AZ

Clinical Trials near Chandler, AZ

Clinical Trials near Tempe, AZ

Clinical Trials near Gilbert, AZ

Clinical Trials near Glendale, AZ

Clinical Trials near Peoria, AZ

Clinical Trials near Sun City, AZ

Clinical Trials near Goodyear, AZ

Clinical Trials near Flagstaff, AZ

Other People Viewed

By Subject

Top Clinical Trials near Vermont

191 Clinical Trials near New Brunswick, NJ

Top Traumatic Brain Injury Clinical Trials

36 Depression Trials near Denver, CO

Top Clinical Trials near Kahului, HI

Top Clinical Trials near South Carolina

Top Oligodendroglioma Clinical Trials

Top Clinical Trials near Fort Mill, SC

192 Clinical Trials near Fredericksburg, TX

Top Clinical Trials near Canton, GA

Top Clinical Trials near Huntsville, TX

Top Clinical Trials near Johnstown, PA

By Trial

AK104 for Cervical Cancer

Chiropractic Care + Tai Chi for Chronic Neck Pain

Exercise Strategy for Cancer Survivors

RSLV-132 for Sjögren's Syndrome

STARS + Maternal Support for Substance Use During Pregnancy

Ibuprofen + Dexamethasone for Lower Back Pain

Plasma Injections for Knee Osteoarthritis

GENUS Stimulation to Prevent Alzheimer's Disease

Glucose Clamp Study for Low Blood Sugar

PFO Closure Devices for Stroke Prevention

Virtual Reality Tool for Cancer

Healthy Lifestyle Program for Childhood Obesity and Asthma

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial